Incanthera Plc · AQUIS:INC
Incanthera — IPO Roadshow (2020)
21 slides from Incanthera's IPO roadshow presentation, 2020
Slide 1: Creating an environment in which cancer cannot survive
Creating an environment in Creating ancannot which cancer environment survive in which cancer cannot survive 2020 IPO Presentation 2018
Slide 2: Providing new cancer treatments through acquisition, preparation and early commercialisation
Providing new cancer treatments through the acquisition, preparation and early commercialisation of targeted medicines 2 Acquire, Prepare, Commercialise
Slide 3: Company Overview
Company Overview • UK oncology focused, targeted drug development company • Acquiring, preparing and commercialising new oncology technologies • Multiple asset portfolio • First commercial deal for Company’s asset (EP0015) signed June 2017 • Near to market asset – possible commercialisation within 1
Slide 4: Origins – Institute of Cancer Therapeutics (ICT) Bradford
Origins – Institute of Cancer Therapeutics (ICT) Bradford • ICT established in 2005 to identify and research unique anticancer technologies • 4-storey purpose-built facility, over 50 research and oncologist specialists • Multi-disciplinary approach covering drug design, synthesis, screening, pharmac
Slide 5: Our Approach
Our Approach • Identify cutting edge technologies in oncology • Acquire intellectual property rights to product opportunities • Prepare technologies to valuation realisation • Commercialise through a partner, securing deal that aims to prioritise further development, marketing and early revenues to
Slide 6: Our Strengths
Our Strengths We have established a broad pipeline portfolio • Not reliant upon one single technology origin • A pipeline of product opportunities from various sources • Future-proofed access to new technologies through deal with the ICT We develop our products with expertise, in preparation for com
Slide 7: How do we achieve this?
How do we achieve this? • Through pro-active identification of novel technology • Through wide-ranging industry experience and relationships which facilitate strategic preparation of the technology for out-licensing • Through a proven ability to commercialise novel technology • Through our experienc
Slide 8: The Team
The Team Tim McCarthy Pawel Zolniercyk Chairman (Board) COO 35 year international career, CEO and CFO IP, Tech Transfer and Project of public and private biotech & healthcare Management specialist, with over companies. Non-Executive Chairman of 10 years experience in IP ImmuPharma plc and Supervisor
Slide 9: Growth through Commercial Deals
Growth through Commercial Deals Year Deal 2010 Company Founded 2011 Pipeline deal - Institute of Cancer Therapeutics (ICT) 2011 Acquisition of EP0015 (VDA - ICT pipeline) 2014 Acquisition of Onco-NX Ltd (Equin programme) 2014 Acquisition of Duo-C technology (ICT pipeline) 2014 Acquisition of Spear T
Slide 10: Product Pipeline
Product Pipeline Acquisition Preparation for Licensing Licensing Platform Product Indication Skin cancers: solar keratosis, Bioequivalence Sol Topical Cream Market Launch melanoma (AK - $3.4bn)* VDA Lung, breast, ovarian cancers Pre-clinical Licensed to & ($5.9bn, $15.3bn, Theranostic $1.6bn)* Ellip
Slide 11: Targeted Technology
Targeted Technology • Unique MOA - pro-drug targeting tumour vasculature • Strong pre-clinical efficacy and safety data • Delivery platform for highly efficacious ‘warheads’ EP0015 • Bio-reductive Prodrug activated by DT-Diaphorase • Target cancers include liver and breast with a potential for paedi
Slide 12: Sol and The Skin Cancer Challenge
Sol and The Skin Cancer Challenge Skin cancer (including solar keratosis) is the most UK SKIN CANCER RATES 2004-2016 (NUMBERS PER 100,000) common form of cancer in white populations, and 30 deaths arising from invasive melanoma are on the increase. 25 • Melanoma has increased by 45% in ten years • M
Slide 13: Our Natural Defence
Our Natural Defence Cells have natural defence and DNA repair capabilities, but this is compromised in skin cells by UV light A natural agent believed to enhance the skin’s defences and DNA repair capabilities, to counter UV effects, has been identified Studies including a Phase 3 clinical trial hav
Slide 14: The Opportunity and the Advantages
The Opportunity and the Advantages Opportunity – Sol A dermatological preparation of the natural agent to offer significant advantages over oral dosing Advantages of Sol over oral dosing vs • Avoidance of known possible side effects of ingestion • Circumvention of first-pass metabolism • Ease of app
Slide 15: Sol Delivers
Sol Delivers Independent Proof of Principle Studies conducted at the UCL London School of Pharmacy using human skin penetration models demonstrate that our advanced formulation technology (Summer 2019): • Exceeds the bioequivalence test • Delivers a topical product for the prevention of actinic kera
Slide 16: Next Steps
Next Steps Numerous milestones over next 18 months Major Players • Avon Products Inc • Bayer Healthcare • Beirsdorf AG • Blistex Inc • Clarins Group Value increase expected • Coty Inc • L’Oreal Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Product Manufacture Storage & Stability Irritancy & Sensitivity Commer
Slide 17: Driving Shareholder Value (Forecast 18 months from IPO)
Driving Shareholder Value (Forecast 18 months from IPO) Recognition of importance of regular, positive newsflow to support increase in valuation: • Product Manufacture – Sol • Storage Stability Data – Sol • Submission of CTA to MHRA for EP0015 • Safety Data –Sol • Commencement of First Time in Man t
Slide 18: Corporate Profile
Corporate Profile • Valuation at last fund raise: £13.5m • Fund Raise: £1.8m • EIS and VCT qualifying • Shareholders: NWF 33.3% UoB 15.4% IMM 14.9% Directors & Mgmt. 7.9% NPIF (Maven) 1.9% University of Salford 1.5% HNWI & Others 25.1% 18 Acquire, Prepare, Commercialise
Slide 19: Use of Funds (18 months)
Use of Funds (18 months) • Fund Raise: £1.8m • R & D: £850k • Board Costs: £160k • Other Salaries: £130k • Overheads: £300k • Costs of Listing: £360k 19 Acquire, Prepare, Commercialise
Slide 20: Investment Case
Investment Case • Differential business model • Acquire, prepare, commercialise • Near to market asset • Sol potential to launch (with commercial partner) within 18 months with numerous milestone opportunities in the interim • Revenue generative through strategic partners (first commercial deal sign
Slide 21: Disclaimer
Disclaimer The information contained in these slides and any accompanying verbal presentation, any question and answer session and any document or material distributed at or in connection with the verbal presentation (together, the “Presentation”) have not been approved by an authorised person withi